|
Intralytix
Wins Army Grant for Salmonella and Shigella Technology
Source
of Article: http://7thspace.com/headlines/313174/intralytix_wins_army_grant_for_salmonella_and_shigella_technology.html
Baltimore, Maryland U.S.A. – June 29,
2009 - - Intralytix, Inc. announced today that it has been awarded a
contract from the U.S. Army to develop a bacteriophage-based food safety
product for reducing or eliminating contamination from pathogenic
Salmonella and Shigella spp. The product would be used to eliminate or
significantly reduce contamination of fruits, vegetables and other food
products.
“We are very pleased with the award because it helps to enrich Intralytix’s
portfolio of phage-based, food safety products, and it demonstrates the
confidence that the U.S. Army has in Intralytix’s leadership in developing
bacteriophage-based preparations for food safety applications for military
and civilian populations,” stated Dr. Alexander Sulakvelidze, Intralytix’s
Vice-President for Research and Development and Chief Scientist. He added:
“We expect that, once developed, this product will significantly improve
the safety of food that may be contaminated with pathogenic salmonella and
shigella. Its anti-salmonella phage component will be useful in reducing
the severity of worldwide salmonellosis outbreaks among civilian and
military populations. Each year, an estimated 1.4 million cases of
salmonellosis occur in the United States alone. Also, its anti-shigella
phage component will to be useful in developing countries where U.S. troops
may be stationed, and/or where shigellosis is endemic. The annual,
worldwide number of Shigella infections is approximately 165 million,
mostly in developing countries, resulting in approximately 1.1 million
deaths.”
“This will be the third phage-based food safety product developed by
Intralytix,” noted the company’s CEO, John Woloszyn. He also noted that “we
have previously received FDA and EPA approvals of our phage-based cocktail
effective against Listeria monocytogenes (“LMP-102”), and the U.S. Army has
supported the development of a second food safety product effective against
E. coli 0157:H7 (“ECP-100”). Commercial sales for LMP-102 have recently commenced
and regulatory approval of ECP-100 is expected in 2009,” he added.
Intralytix, Inc is a biotechnology company focused on improving human
health through the development and commercialization of innovative products
for food safety and human therapeutics using its core bacteriophage (or
phage) technology platform.
For more information, contact John Woloszyn (410-625-0300 /
jwoloszy@intralytix.com) or Dr. Alexander Sulakvelidze (410-625-2533 /
asulakvelidze@intralytix.com).
|
|
|
